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end of infusion, 4 hr and 6 hr) with the addition of a trough level 
for Dose 9 calculation. LSS AUC were calculated by: AUCinf = 
AUC0-6hr + AUCext, where AUC0-6hr was estimated using the 
linear trapezoidal rule and AUCext was computed by the ratio of 
the busulfan concentration at Hr 6 and the elimination rate con- 
stant, lz.. RESULTS: The LSS AUC showed good correlation 
with the full Dose i AUC (r2=0.96) and Dose 9 AUC (r2=0.97). 
For Dose 1 and Dose 9 AUCs, 22/24 and 23/23 peds had differ- 
ences of <10% calculated by the LSS, respectively. CONCLU-  
SIONS: The LSS accurately predicted 1VBU SE. Using a dosing 
strategy" of 1.1 mg/kg for <12 kg and 0.8 mg/kg for >12kg patients, 
clinical application of this approach should effcctively guide dose 
adjustment and SE targeting in peds. 
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION SUCCESS- 
FULLY CORRECTS CONGENITAL IMMUNODEFICIENCY SYNDROMES 
Km'tzl, erg, J.; Szabolcs, P.; Driscoll, T.; M,stafa, M.; Arcbamba,lt, 
B.; ~llartM, P.L. Pediatric.r, D~ke University Medical Celtter, 
Din'ham, NC. 
Pediatric patients with congenital Jmmunodeficiency s ndromes 
die early in life. Allogeneic stem cell transplantation (SCT) is cura- 
tive, but many pts lack a suitably matched living related or unrelated 
donor. Some children lacking matched onors have been transpIant- 
ed with T cell depleted haplo-identical stem cells from a parent, but 
despite ngTaftment of donor T-cells, only 3 0% of these pts reconsti- 
tute B-cells. Unrelated cord blood (UCB) is a source of allogeneic 
donor cells that can he used without full HLA matching. We report 
our results using UCB transplantation after myeloablative 
chemotherapy (busulfan/cytoxan/ATG) as primary therapy for 25 
pediatric pts with various congenital immunodeficiency syndromes 
over the past 7 years. Pts ranged in age from 4 months to 4 years and 
were diagnosed with SCID (n=3), CID (6), Leukocyte adhesion defi- 
ciency (1), Familial erythropahgocytic lymphohistiocytosis (4), Wis- 
cott Aldrich Syndrome (10), and PNP Deficiency (1). They were 
transplanted with grafts matching at 3 (11=1), 4 (11), 5 (8) or 6 (1) 
HLA loci. Grafts delivered higher cell doses than typically seen with 
UCB grafts because the pts were small. The median cell dose was 
10.38 x 10e7 cells/kg containing 5.94 x 10e5 CD34 cells/kg. 
Cyclosporine and solmnedrol were given for GvItD prophylaxis. 
Engraftment of neutrophils (ANC 500/nL) occurred in all pts in a 
median of 18 days (range 7-45) and of platelets (nntransfilsed cotmt 
of 50K/uL) in 67 days (range 31-189). Grades II-IV acute GvHD 
developed in 4 pts and limited chronic GvHD of the skin developed 
in all surviving pts with WAS and 2 pts with CID. Five patients died 
of infection (n=3), EBV-LPD with cGvI iD (n=l) or VOD 
(n=l)within the first few months post transplant. The remaining 
patients are surviving with 100% chimeric grafts for a median of 4 
years with full T and B cell immune reconstimtion. Surviving pts 
have been successfially immunized with ldlled and live vaccines and 
have not encountered late opportunistic nfections. W'e conclude that 
UCB is particularly suited for patients with congenital imlnm~odefi- 
ciency syndromes. They experience faster engraftment and low prob- 
abilities of severe GvHD. UCB transplantation should be considered 
for all such patients lacking a matched related stem cell donor. 
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PHARMACOKINETIC STUDY OF RABBIT ANTI-THYMOCYTE GLOBULIN 
IN CHILDREN UNDERGOING BONE MARROW TRANSPLANTATION 
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Q,im2, M.A.; Horn, B.dM Pediatrics, UCSF, &t, Fl:nm'isco, Gd. 
Introduction: Pharmacokinetic data of rabbit ATG in children 
receiving bone marrow transplantation, especially in relation to 
engraftment and the development of acute GVHD, is lacking. We 
report our preliminary results on five children using rabbit ATG 
as part of the conditioning regimen. Patients underwent bone 
marrow transplantation between March and July of 2002. We fol- 
lowed the sermn rabbit ATG levels (reported as the percent of 
rabbit ATG remaining up to six months post transplantation), 
engraftment, and incidence of acute GVHD. Method: All patients 
received a conditioning regimen that included busulfan, fludara- 
bine and rabbit ATG. Four doses of rabbit ATG, 0.Smg/kg on day 
-4 and 2.5mg/kg on days ~3 to -1, for a total dose of 8mg/kg were 
given. Rabbit IgG serum level was deterntined by ELISA. The 
percent of rabbit ATG remaining after transplantation  days 7, 
14, 28 and monthly until six months post transplant was calculated 
based on rabbit IgG level detected on day 0. Result: Four patients 
had 6/6 matched unrelated BMT donors, and one patient had 
matched related donor. The  diagnosis included SCID (n-2), 
Hnrler's syndrome (n=l), CML (n-i),  and Clnediak-Iligashi dis- 
ease (n=l). The median age was 2.4 years (range from 1 to 5 years) 
at the time of transplantation. All patients engrafted with a median 
time to engraftment of 20 days ranging ftom 18 to 24 days. Only 
one patient (no.5) developed cutaneous acute GVHD (grade II) 
on day +42. The percentage of rabbit ATG remaining post trans- 
plantation for all patients is shown in Table 1. Rabbit ATG was 
detected in all five patients up to 100 days post transplantation a d 
in 4/4 patients at I60 days post transplant. Campbell et al. detect- 
ed rabbit IgG in nlost of 79 adults patients for more than 90 days 
after transplantation. In our study, rabbit ATG can be detected 
even after 160 days post transplantation in all patients tested. The 
incidence of acute GVHD in this limited cohort was low. We 
continue to enroll patients into the study to assess if the post 
transplant seruln rabbit ATG levels can affect the incidence of 
acute GVHD. Table 1 Presents the % of Rabbit ATG remaining 
in sermn post-transplant, compared to level on day 0 
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PHARMACOKINETICS OF IV BUSULFAN (IV BU) IN PEDIATRIC 
INFANTS (< IO-KILOGRAM BODY WEIGHT) UNDERGOING STEM 
CELL TRANSPLANT 
Dalle, ft.1; ~'fgdl, D.:; Daval, M.1; Tbeoret, }:s; Tto,lor, C.-'; f'~t~/~oJ~, 
M. 1; 3/ioghrabi, A.I; La1"ocq,e, D.I; ChampagTze, M.A.1 1. hematology 
alzd oncol%[y, Sai*lte ff lsti,e Hospit,d, Molm'eal, QC, Ca',ada; 
2. Methodist Chilc~re, 's Hospital of So~M~ Texas, Nz, A,tor~io, TX. 
Busulf:an is an important component of myeloablative regimens 
for patients undergoing HSC transplantation. Use of oral busulfan 
is limited by a wide inter-patient and intra-patient variability in 
disposition. A parenteral form was developed to overcome these 
difficulties. For pediatric patients, a posology of 0.8 (children >3 
years) to 1.0 mg/kg (children <3 years) x 16 has been suggested 
(Wall, ASH 2000). However, limited information is available on 
its use in small children. We therefore retrospectivally studied 
pharmaco~netics of IV Bu (Busulfex@, Orphan Medical) in 14 
children < 1 year of age and < 10 kg (median age 4.8 months, 
median weight 5.9 kg) undergoing stem cell transplantation for 
severe combined immunodeficiency (n=6), hematological malig- 
nancies (n-3), inherited syndrome (n=3) or other (n=2). Drug was 
initially given at 1 mg/kg/dose (2 hour-infilsion) every 6 hours x 
16 doses (initial dosing was 0.8 mg/kg/dose in 3). Serial blood 
specimens were obtained and plasma busulfan values were deter- 
mined by HPLC.  The target AUC was 600-900 btMol.mn for 
patients with sibling donor and 900-1300 for the others. Main 
clinical characteristics and pharmacological results are summa- 
rized in table 1. Dose adjustment was subsequently made accord- 
ing to the initial results. IV Bu dose was decreased in 7, 
unchanged in 5 and increased in 2. Only one patient received 
more than the intended 16 mg/kg total dose. Median total dose 
given in this cohort was 13.8 mg/kg. One patient experienced a 
severe VOD. Donor engraftment was documented in 100% of 
patients. Conclusion: use of IV Bu in infants is safe but pharmaco- 
kinetic guided dose adjustment appears necessary. The current 
recommended ose of Img/kg/dose for children under 3 years 
appears to be associated with dosage higher than targeted. 
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